Uveitis

In a new study, inserting the XEN-45 implant in patients with uncontrolled uveititc glaucoma prevented conventional glaucoma surgery in 83.3% of patients.

A systematic review and meta-analysis provides insight into the potential for increased risk of noninfectious uveitis among people with vitamin D deficiency.

After years 1, 3, and 5, patients with diabetic retinopathy patients had increased odds of depression and suicide, patients with glaucoma had increased odds for all mental health conditions with higher odds for suicide or suicide ideation, and patients with AMD had increased odds for depression.

A recent nationwide cohort study identified statistically significant associations between IBD and DED, as well as increased risks of corneal surface damage.

Intravitreal corticosteroid injections improved vision in eyes with persistent or recurrent uveitis-related macular edema better than methotrexate or ranibizumab injections.

An analysis of real-life data indicates the role of adalimumab in reducing the frequency and/or severity of ocular flares in pediatric patients with non-infectious non-anterior uveitis.

Data from the United Kingdom indicate Amgevita is safe and effective for non-infectious uveitis with non-inferiority to originator adalimumab, but a significant number of patients requested to switch back due to adverse events.

A 0.18-mg implant may be an effective option in managing noninfectious uveitis affecting the posterior segment.

Eyes with concurrent uveitis in a Swedish cohort had worse BCVA prior to and following cataract surgery, although visual improvement was greater compared to control eyes.

The retrospective study reported the presence of ADAs was associated with lower drug levels, and higher ADA levels were associated with increased risk of TNFi therapy failure.

The findings may support the use of macular imaging for monitoring at the time of glaucoma diagnosis and for monitoring the rate of GCC thinning.

Study data suggest the observed to expected ratio of VAU for the United States cases reports was comparable for all 3 approved vaccines.

The presence of SRF or PED was not significantly associated with worse visual acuity at any time point during the observation period.

Over a 40-year follow-up, approximately one-quarter of the study cohort with juvenile arthritis were reported to have active uveitis.

71.6% of patients showed a clinically meaningful improvement in total corneal fluorescein staining at 4 weeks after using the ophthalmic solution.

Data show visual display terminal use causes dry eye disease mainly through impaired blinking patterns.

The resolution of excess central retinal thickness in response to anti-VEGF therapy and the treatment burden were additionally similar between the 2 groups.

An increase in annual prevalence of beneficiaries with diabetes was observed in those who had ≥1 claim for DME (1.0% to 3.3%) and DME/VTDR (2.8% to 4.3%).

AGN-190584 showed superiority in efficacy over vehicle in mesopic DCNVA on day 30 with an acceptable safety profile for patients with presbyopia.

African American individuals and Hispanic individuals were more likely than non-Hispanic White individuals to report not being able to afford medications.

The annual rate of visual field loss was −0.15 dB for the slow OCTA progressors and −0.43 dB for the fast OCTA progressors.

Future clinical trials may be necessary to confirm if 1 treatment is superior to the other to a clinically relevant degree in patients with thyroid eye disease.

Thinner RNFL and GCL were associated with lower Full Scale IQ in childhood and at age 45 years, while thinner RNFL in middle age was associated with greater decline in processing speed.

Data show the 5-year cumulative incidence of glaucoma was 46% among children with bilateral aphakia and 25% with unilateral aphakia.

Data show ≥60% of eligible faricimab patients with DME could extend treatment to every 4 months, while 95% of ranibizumab implants in wetAMD treatment maintained a six-month schedule.

Dr. Brown discusses the most common conditions of patients treated for ocular trauma and highlights the range of performed procedures in the ED.

The study suggested children born extremely premature may remain "preterm for life," with ophthalmic sequelae persisting into adulthood.

A multitude of promising new investigative therapies are on the horizon for inherited retinal disease.

Dr. Modi discusses the pending approval of faricimab for nAMD, DME treatment and highlights important observations from phase 3 data.

Outlook Therapeutics is expected to submit a BLA to the FDA for the investigative ophthalmic bevacizumab-vikg formulation (ONS-5010).